title: Phospholipase A2 levels in acute chest syndrome of sickle cell disease.
abstract: Acute chest syndrome (ACS) is associated with significant morbidity and is the leading cause of death in patients with sickle cell disease (SCD). Recent reports suggest that bone marrow fat embolism can be detected in many cases of severe ACS. Secretory phospholipase A2 (sPLA2) is an important inflammatory mediator and liberates free fatty acids, which are felt to be responsible for the acute lung injury of the fat embolism syndrome. We measured SPLA2 levels in 35 SCD patients during 20 admissions for ACS, 10 admissions for vaso-occlusive crisis, and during 12 clinic visits when patients were at the steady state. Eleven non-SCD patients with pneumonia were also evaluated. To determine if there was a relationship between sPLA2 and the severity of ACS we correlated SPLA2 levels with the clinical course of the patient. In comparison with normal controls (mean = 3.1 +/- 1.1 ng/mL), the non-SCD patients with pneumonia (mean = 68.6 +/- 82.9 ng/mL) and all three SCD patient groups had an elevation of SPLA2 (steady state mean = 10.0 +/- 8.4 ng/mL; vaso-occlusive crisis mean = 23.7 +/- 40.5 ng/mL; ACS mean = 336 +/- 209 ng/mL). In patients with ACS sPLA2 levels were 100-fold greater than normal control values, 35 times greater than values in SCD patients at baseline, and five times greater than non-SCD patients with pneumonia. The degree of SPLA2 elevation in ACS correlated with three different measures of clinical severity and, in patients followed sequentially, the rise in SPLA2 coincided with the onset of ACS. The dramatic elevation of SPLA2 in patients with ACS but not in patients with vaso-occlusive crisis or non-SCD patients with pneumonia and the correlation between levels of SPLA2 and clinical severity suggest a role for SPLA2 in the diagnosis and, perhaps, in the pathophysiology of patients with ACS.
authors.affiliation: Department of Hematology/Oncology, Children's Hospital Oakland, CA 94609 USA.
authors.forename: L A
authors.initials: LA
authors.lastname: Styles
authors.forename: C G
authors.initials: CG
authors.lastname: Schalkwijk
authors.forename: A J
authors.initials: AJ
authors.lastname: Aarsman
authors.forename: E P
authors.initials: EP
authors.lastname: Vichinsky
authors.forename: B H
authors.initials: BH
authors.lastname: Lubin
authors.forename: F A
authors.initials: FA
authors.lastname: Kuypers
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000755:Anemia, Sickle Cell / Q000150:complications* / Q000201:enzymology*; D002648:Child; D002675:Child, Preschool; D004620:Embolism, Fat / Q000201:enzymology / Q000209:etiology; D005230:Fatty Acids, Nonesterified / Q000378:metabolism; D005260:Female; D006801:Humans; D007223:Infant; D007249:Inflammation / Q000201:enzymology; D007511:Ischemia / Q000201:enzymology / Q000209:etiology; D008171:Lung Diseases / Q000201:enzymology / Q000209:etiology* / Q000503:physiopathology; D008297:Male; D010741:Phospholipases A / Q000097:blood*; D054467:Phospholipases A2; D011014:Pneumonia / Q000201:enzymology; D011655:Pulmonary Embolism / Q000201:enzymology / Q000209:etiology
chemical_list: D005230:Fatty Acids, Nonesterified; D010741:Phospholipases A; D054467:Phospholipases A2